Tiziana Life Sciences Ltd TLSA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -119.94% | -119.94% | -77.54% | -77.54% | -21.01% |
| Total Depreciation and Amortization | 79.55% | 79.55% | 135.48% | 135.48% | 41.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 511.03% | 511.03% | -74.91% | -74.91% | -87.39% |
| Change in Net Operating Assets | 237.09% | 237.09% | 312.79% | 312.79% | -200.71% |
| Cash from Operations | -7.81% | -7.81% | -212.77% | -212.77% | -1,805.75% |
| Capital Expenditure | -900.00% | -900.00% | -200.00% | -200.00% | 57.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -102.08% | -102.08% | 3,360.00% | 3,360.00% | 20,671.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -170.83% | -170.83% | -105.56% | -105.56% | 30.43% |
| Issuance of Common Stock | -10.35% | -10.35% | -40.90% | -40.90% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -11.54% | -11.54% | -41.49% | -41.49% | 10,766.67% |
| Foreign Exchange rate Adjustments | -33.64% | -33.64% | -966.67% | -966.67% | 129.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -123.59% | -123.59% | -224.94% | -224.94% | 6,754.72% |